1. Hida K, Maishi N, Sakurai Y, Hida Y, Harashima H (2016) Heterogeneity of tumor endothelial cells and drug delivery. Adv Drug Deliv Rev 99:140–147
2. Song W, Tang Z, Zhang D, Yu H, Chen X (2015) Coadministration of vascular disrupting agents and nanomedicines to eradicate tumors from peripheral and central regions. Small 11:3755–3761
3. Kratz F, Elsadek B (2012) 8-Clinical impact of serum proteins on drug delivery. J Control Release 161:429–445
4. Koopaei MN, Dinarvand R, Amini M, Rabbani H, Emami S, Ostad SN et al (2011) 9-Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies. Int J Nanomedicine 6:1903–1912
5. Duro-Castano A, Gallon E, Decker C, Vicent MJ (2017) Modulating angiogenesis with integrin-targeted nanomedicines. Adv Drug Deliv Rev,
https://doi.org/10.1016/j.addr.2017.05.008